IBDEI0CO ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5672,1,3,0)
 ;;=3^275.3
 ;;^UTILITY(U,$J,358.3,5672,1,4,0)
 ;;=4^HYPOPHOSPHATEMIA
 ;;^UTILITY(U,$J,358.3,5672,2)
 ;;=^93796
 ;;^UTILITY(U,$J,358.3,5673,0)
 ;;=276.8^^28^374^15
 ;;^UTILITY(U,$J,358.3,5673,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5673,1,3,0)
 ;;=3^276.8
 ;;^UTILITY(U,$J,358.3,5673,1,4,0)
 ;;=4^HYPOPOTASSEMIA/HYPOKALEMIA
 ;;^UTILITY(U,$J,358.3,5673,2)
 ;;=^60611
 ;;^UTILITY(U,$J,358.3,5674,0)
 ;;=276.52^^28^374^16
 ;;^UTILITY(U,$J,358.3,5674,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5674,1,3,0)
 ;;=3^276.52
 ;;^UTILITY(U,$J,358.3,5674,1,4,0)
 ;;=4^HYPOVOLEMIA
 ;;^UTILITY(U,$J,358.3,5674,2)
 ;;=^332744
 ;;^UTILITY(U,$J,358.3,5675,0)
 ;;=276.4^^28^374^17
 ;;^UTILITY(U,$J,358.3,5675,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5675,1,3,0)
 ;;=3^276.4
 ;;^UTILITY(U,$J,358.3,5675,1,4,0)
 ;;=4^MIXED ACID-BASE DISORDER
 ;;^UTILITY(U,$J,358.3,5675,2)
 ;;=^267945
 ;;^UTILITY(U,$J,358.3,5676,0)
 ;;=588.1^^28^374^18
 ;;^UTILITY(U,$J,358.3,5676,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5676,1,3,0)
 ;;=3^588.1
 ;;^UTILITY(U,$J,358.3,5676,1,4,0)
 ;;=4^NEPHROGEN DIABETES INSIP
 ;;^UTILITY(U,$J,358.3,5676,2)
 ;;=^276848
 ;;^UTILITY(U,$J,358.3,5677,0)
 ;;=276.50^^28^374^19
 ;;^UTILITY(U,$J,358.3,5677,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5677,1,3,0)
 ;;=3^276.50
 ;;^UTILITY(U,$J,358.3,5677,1,4,0)
 ;;=4^VOLUME DEPLETION NOS
 ;;^UTILITY(U,$J,358.3,5677,2)
 ;;=^332840
 ;;^UTILITY(U,$J,358.3,5678,0)
 ;;=275.2^^28^374^7
 ;;^UTILITY(U,$J,358.3,5678,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5678,1,3,0)
 ;;=3^275.2
 ;;^UTILITY(U,$J,358.3,5678,1,4,0)
 ;;=4^HYPER/HYPOMAGNESEMIA
 ;;^UTILITY(U,$J,358.3,5678,2)
 ;;=^35626
 ;;^UTILITY(U,$J,358.3,5679,0)
 ;;=584.9^^28^375^1
 ;;^UTILITY(U,$J,358.3,5679,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5679,1,3,0)
 ;;=3^584.9
 ;;^UTILITY(U,$J,358.3,5679,1,4,0)
 ;;=4^ACUTE RENAL FAILURE NOS
 ;;^UTILITY(U,$J,358.3,5679,2)
 ;;=^338532
 ;;^UTILITY(U,$J,358.3,5680,0)
 ;;=285.21^^28^375^2
 ;;^UTILITY(U,$J,358.3,5680,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5680,1,3,0)
 ;;=3^285.21
 ;;^UTILITY(U,$J,358.3,5680,1,4,0)
 ;;=4^ANEMIA SECONDARY/ESRD
 ;;^UTILITY(U,$J,358.3,5680,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,5681,0)
 ;;=285.29^^28^375^3
 ;;^UTILITY(U,$J,358.3,5681,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5681,1,3,0)
 ;;=3^285.29
 ;;^UTILITY(U,$J,358.3,5681,1,4,0)
 ;;=4^ANEMIA SECONDARY/OTH CHR ILLNESS
 ;;^UTILITY(U,$J,358.3,5681,2)
 ;;=^334228
 ;;^UTILITY(U,$J,358.3,5682,0)
 ;;=585.9^^28^375^10
 ;;^UTILITY(U,$J,358.3,5682,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5682,1,3,0)
 ;;=3^585.9
 ;;^UTILITY(U,$J,358.3,5682,1,4,0)
 ;;=4^CHRONIC KIDNEY DIS NOS
 ;;^UTILITY(U,$J,358.3,5682,2)
 ;;=^332812
 ;;^UTILITY(U,$J,358.3,5683,0)
 ;;=585.5^^28^375^9
 ;;^UTILITY(U,$J,358.3,5683,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5683,1,3,0)
 ;;=3^585.5
 ;;^UTILITY(U,$J,358.3,5683,1,4,0)
 ;;=4^CHR KIDNEY DIS STAGE V
 ;;^UTILITY(U,$J,358.3,5683,2)
 ;;=^332811
 ;;^UTILITY(U,$J,358.3,5684,0)
 ;;=585.1^^28^375^5
 ;;^UTILITY(U,$J,358.3,5684,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5684,1,3,0)
 ;;=3^585.1
 ;;^UTILITY(U,$J,358.3,5684,1,4,0)
 ;;=4^CHR KIDNEY DIS STAGE I
 ;;^UTILITY(U,$J,358.3,5684,2)
 ;;=^332807
 ;;^UTILITY(U,$J,358.3,5685,0)
 ;;=585.2^^28^375^6
 ;;^UTILITY(U,$J,358.3,5685,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5685,1,3,0)
 ;;=3^585.2
 ;;^UTILITY(U,$J,358.3,5685,1,4,0)
 ;;=4^CHR KIDNEY DIS STAGE II
 ;;^UTILITY(U,$J,358.3,5685,2)
 ;;=^332808
 ;;^UTILITY(U,$J,358.3,5686,0)
 ;;=585.3^^28^375^7
 ;;^UTILITY(U,$J,358.3,5686,1,0)
 ;;=^358.31IA^4^2
 ;;
 ;;$END ROU IBDEI0CO
